Hypoxia-Inducible Factor in Thyroid Carcinoma

Intratumoural hypoxia (low oxygen tension) is associated with aggressive disease and poor prognosis. Hypoxia-inducible factor-1 is a transcription factor activated by hypoxia that regulates the expression of genes that promote tumour cell survival, progression, metastasis, and resistance to chemo/radiotherapy. In addition to hypoxia, HIF-1 can be activated by growth factor-signalling pathways such as the mitogen-activated protein kinases- (MAPK-) and phosphatidylinositol-3-OH kinases- (PI3K-) signalling cascades. Mutations in these pathways are common in thyroid carcinoma and lead to enhanced HIF-1 expression and activity. Here, we summarise current data that highlights the potential role of both hypoxia and MAPK/PI3K-induced HIF-1 signalling in thyroid carcinoma progression, metastatic characteristics, and the potential role of HIF-1 in thyroid carcinoma response to radiotherapy. Direct or indirect targeting of HIF-1 using an MAPK or PI3K inhibitor in combination with radiotherapy may be a new potential therapeutic target to improve the therapeutic response of thyroid carcinoma to radiotherapy and reduce metastatic burden.

[1]  Jin-Rong Zhou,et al.  Smad4 inactivation promotes malignancy and drug resistance of colon cancer. , 2011, Cancer research.

[2]  Emma Lundsmith,et al.  Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice , 2011, Proceedings of the National Academy of Sciences.

[3]  M. Schlumberger,et al.  Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. , 2010, The Journal of clinical endocrinology and metabolism.

[4]  Guoqiang Chen,et al.  Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in migration/invasion of colorectal cancer cells. , 2010, Carcinogenesis.

[5]  M. van Engeland,et al.  VHL and HIF signalling in renal cell carcinogenesis , 2010, The Journal of pathology.

[6]  Matthew D. Ringel,et al.  The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors , 2010, Molecular and Cellular Endocrinology.

[7]  Torgny Stigbrand,et al.  Radiation-induced cell death mechanisms , 2010, Tumor Biology.

[8]  F. Cappello,et al.  BRAFV600E mutation influences hypoxia-inducible factor-1α expression levels in papillary thyroid cancer , 2010, Modern Pathology.

[9]  W. Linehan,et al.  The genetic basis of kidney cancer: a metabolic disease , 2010, Nature Reviews Urology.

[10]  A. Józkowicz,et al.  HIF-1 and HIF-2 transcription factors — Similar but not identical , 2010, Molecules and cells.

[11]  Kam‐Tsun Tang,et al.  BRAF Mutation in Papillary Thyroid Carcinoma: Pathogenic Role and Clinical Implications , 2010, Journal of the Chinese Medical Association : JCMA.

[12]  D. Pfister,et al.  Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Semenza.  Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics , 2010, Oncogene.

[14]  G. Brabant,et al.  Expression of hypoxia-inducible factor 1α in thyroid carcinomas , 2010, Endocrine-related cancer.

[15]  J. Griffin,et al.  Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion , 2009, British Journal of Cancer.

[16]  Tetsuhiro Tanaka,et al.  The human HIF (hypoxia-inducible factor)-3alpha gene is a HIF-1 target gene and may modulate hypoxic gene induction. , 2009, The Biochemical journal.

[17]  M. Pino,et al.  Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer. , 2009, Cancer research.

[18]  M. Borrello,et al.  Molecular pathology of differentiated thyroid cancer. , 2009, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[19]  Misa Nakamura,et al.  Targeting of the BRAF gene in papillary thyroid carcinoma (review). , 2009, Oncology reports.

[20]  W. Hsu,et al.  Prognostic significance of hypoxia-inducible factor-1α, TWIST1 and Snail expression in resectable non-small cell lung cancer , 2009, Thorax.

[21]  R. Muschel,et al.  Tumor vascular changes mediated by inhibition of oncogenic signaling. , 2009, Cancer research.

[22]  C. Stratakis,et al.  SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma–paraganglioma syndromes , 2009, Journal of internal medicine.

[23]  A. Tee,et al.  Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. , 2009, Cellular signalling.

[24]  F. B. Davis,et al.  L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. , 2009, American journal of physiology. Cell physiology.

[25]  Jiachao Liang,et al.  Phase II trial of sorafenib in metastatic thyroid cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Hiraoka,et al.  The Akt/mTOR Pathway Assures the Synthesis of HIF-1α Protein in a Glucose- and Reoxygenation-dependent Manner in Irradiated Tumors* , 2009, Journal of Biological Chemistry.

[27]  Yuquan Wei,et al.  Mechanism of Cancer Cell Adaptation to Metabolic Stress , 2009, Molecular & Cellular Proteomics.

[28]  A. Harris,et al.  Targeting tumour hypoxia in breast cancer. , 2008, European journal of cancer.

[29]  J. Chávez,et al.  Mitochondria and Hypoxia‐induced Gene Expression Mediated by Hypoxia‐inducible Factors , 2008, Annals of the New York Academy of Sciences.

[30]  N. Mitsiades,et al.  Molecular pathology of thyroid cancer: diagnostic and clinical implications. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[31]  M. Celeste Simon,et al.  The impact of O2 availability on human cancer , 2008, Nature Reviews Cancer.

[32]  W. Kaelin.  The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer , 2008, Nature Reviews Cancer.

[33]  Andrea B Troxel,et al.  Phase II trial of sorafenib in advanced thyroid cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  H. Yasuda,et al.  Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. , 2008, Nitric oxide : biology and chemistry.

[35]  K. Cengel,et al.  Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. , 2008, Cancer research.

[36]  J. Bussink,et al.  Molecular aspects of tumour hypoxia , 2008, Molecular oncology.

[37]  M. Ringel,et al.  Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. , 2008, Endocrinology and metabolism clinics of North America.

[38]  J. Fandrey,et al.  Thyroid hormone induces hypoxia-inducible factor 1alpha gene expression through thyroid hormone receptor beta/retinoid x receptor alpha-dependent activation of hepatic leukemia factor. , 2008, Endocrinology.

[39]  V. Haase,et al.  The VHL tumor suppressor and HIF: insights from genetic studies in mice , 2008, Cell Death and Differentiation.

[40]  M. Simon,et al.  Biology of hypoxia-inducible factor-2α in development and disease , 2008, Cell Death and Differentiation.

[41]  K. Shokat,et al.  Characterization of structurally distinct, isoform-selective phosphoinositide 3′-kinase inhibitors in combination with radiation in the treatment of glioblastoma , 2008, Molecular Cancer Therapeutics.

[42]  J. Harney,et al.  Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats. , 2008, The Journal of clinical investigation.

[43]  David J. Arenillas,et al.  Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer , 2008, Journal of Cell Science.

[44]  A. Tee,et al.  Hypoxia-inducible Factor 1α Is Regulated by the Mammalian Target of Rapamycin (mTOR) via an mTOR Signaling Motif* , 2007, Journal of Biological Chemistry.

[45]  P. Opolon,et al.  Radiation and inhibition of angiogenesis by canstatin synergize to induce HIF-1alpha-mediated tumor apoptotic switch. , 2007, The Journal of clinical investigation.

[46]  Wei Wang,et al.  High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. , 2007, The Journal of clinical endocrinology and metabolism.

[47]  J. Pastorek,et al.  Carbonic anhydrase inhibitors and the management of cancer. , 2007, Current topics in medicinal chemistry.

[48]  R. Koos,et al.  Estrogen-induced activation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor expression, and edema in the uterus are mediated by the phosphatidylinositol 3-kinase/Akt pathway. , 2007, Endocrinology.

[49]  Y. Nikiforov,et al.  RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. , 2007, Endocrinology.

[50]  A. El‐Naggar,et al.  Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer , 2007, Clinical Cancer Research.

[51]  C. Scrideli,et al.  Prognostic significance of co-overexpression of the EGFR/IGFBP-2/HIF-2A genes in astrocytomas , 2007, Journal of Neuro-Oncology.

[52]  J. Pouysségur,et al.  Harnessing the hypoxia-inducible factor in cancer and ischemic disease. , 2007, Biochemical pharmacology.

[53]  A. C. Williams,et al.  Interaction between β-catenin and HIF-1 promotes cellular adaptation to hypoxia , 2007, Nature Cell Biology.

[54]  R. Reed,et al.  Inhibition of carcinoma cell‐derived VEGF reduces inflammatory characteristics in xenograft carcinoma , 2006, International journal of cancer.

[55]  G. Panayotou,et al.  Identification of MAPK Phosphorylation Sites and Their Role in the Localization and Activity of Hypoxia-inducible Factor-1α* , 2006, Journal of Biological Chemistry.

[56]  Å. Borg,et al.  Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. , 2006, Cancer cell.

[57]  Fatima Mechta-Grigoriou,et al.  Redox regulation of the hypoxia-inducible factor , 2006, Biological chemistry.

[58]  Thomas S. Scanlan,et al.  Rapid nongenomic actions of thyroid hormone , 2006, Proceedings of the National Academy of Sciences.

[59]  Rosa Bernardi,et al.  PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR , 2006, Nature.

[60]  Alexandra M. Dumitrescu,et al.  Thyroid hormone mediated changes in gene expression can be initiated by cytosolic action of the thyroid hormone receptor β through the phosphatidylinositol 3-kinase pathway , 2006, Nuclear receptor signaling.

[61]  C. Shimizu,et al.  Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients , 2006, Breast Cancer Research and Treatment.

[62]  M. Wood,et al.  Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection. , 2006, Cancer research.

[63]  M. Dewhirst,et al.  HIF-1 and tumour radiosensitivity , 2006, British Journal of Cancer.

[64]  J. Pouysségur,et al.  Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.

[65]  Quynh-Thu Le,et al.  Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.

[66]  Tak W. Mak,et al.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.

[67]  B. Kim,et al.  Increased expression of pAKT is associated with radiation resistance in cervical cancer , 2006, British Journal of Cancer.

[68]  A. Harris,et al.  Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[70]  Sheue-yann Cheng,et al.  Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[71]  J. Erler,et al.  Reversing Hypoxic Cell Chemoresistance in Vitro Using Genetic and Small Molecule Approaches Targeting Hypoxia Inducible Factor-1 , 2006, Molecular Pharmacology.

[72]  Christopher J Schofield,et al.  Signalling hypoxia by HIF hydroxylases. , 2005, Biochemical and biophysical research communications.

[73]  Kiichi Hirota,et al.  Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases. , 2005, Biochemical and biophysical research communications.

[74]  Eyal Gottlieb,et al.  Mitochondrial tumour suppressors: a genetic and biochemical update , 2005, Nature Reviews Cancer.

[75]  J. Vieira,et al.  Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. , 2005, European journal of endocrinology.

[76]  I. Stratford,et al.  Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cells. , 2005, International journal of radiation oncology, biology, physics.

[77]  A. Ardizzoni,et al.  Topotecan in the treatment of recurrent small cell lung cancer: an update. , 2004, The oncologist.

[78]  P. Vaupel,et al.  Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. , 2004, The oncologist.

[79]  B. Brüne,et al.  Thyroid hormone induces erythropoietin gene expression through augmented accumulation of hypoxia-inducible factor-1. , 2004, American journal of physiology. Regulatory, integrative and comparative physiology.

[80]  V. Erdmann,et al.  Differentiating the functional role of hypoxia‐inducible factor (HIF)‐1α and HIF‐2α (EPAS‐1) by the use of RNA interference: erythropoietin is a HIF‐2α target gene in Hep3B and Kelly cells , 2004 .

[81]  M. Dewhirst,et al.  Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. , 2004, Cancer cell.

[82]  F. Peale,et al.  Expression of vascular endothelial growth factor, hypoxia inducible factor 1α, and carbonic anhydrase IX in human tumours , 2004, Journal of Clinical Pathology.

[83]  B. Hemmings,et al.  Structure, regulation and function of PKB/AKT--a major therapeutic target. , 2004, Biochimica et biophysica acta.

[84]  M. Ashcroft,et al.  Hypoxia‐inducible factor‐1 and oncogenic signalling , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[85]  A. Pasquini,et al.  Increased expression of Met protein is associated with up‐regulation of hypoxia inducible factor‐1 (HIF‐1) in tumour cells in papillary carcinoma of the thyroid , 2004, The Journal of pathology.

[86]  M. Abend.  Reasons to reconsider the significance of apoptosis for cancer therapy , 2003, International journal of radiation biology.

[87]  Brian Keith,et al.  Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation , 2003, Molecular and Cellular Biology.

[88]  William R Sellers,et al.  TSC2 regulates VEGF through mTOR-dependent and -independent pathways. , 2003, Cancer cell.

[89]  B. Brüne,et al.  Nitric oxide impairs normoxic degradation of HIF-1alpha by inhibition of prolyl hydroxylases. , 2003, Molecular biology of the cell.

[90]  F. B. Davis,et al.  Identification of the putative MAP kinase docking site in the thyroid hormone receptor-beta1 DNA-binding domain: functional consequences of mutations at the docking site. , 2003, Biochemistry.

[91]  D. Tindall,et al.  The role of PTEN in the progression and survival of prostate cancer. , 2003, Minerva endocrinologica.

[92]  K. Jungermann,et al.  Reactive oxygen species modulate HIF-1 mediated PAI-1 expression: involvement of the GTPase Rac1 , 2003, Thrombosis and Haemostasis.

[93]  N. Sang,et al.  MAPK Signaling Up-regulates the Activity of Hypoxia-inducible Factors by Its Effects on p300* , 2003, The Journal of Biological Chemistry.

[94]  J. Klco,et al.  Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. , 2003, Molecular cancer research : MCR.

[95]  M. Cakir,et al.  Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[96]  M. Prat,et al.  Papillary carcinoma of the thyroid: evidence for a role for hepatocyte growth factor (HGF) in promoting tumour angiogenesis , 2003, The Journal of pathology.

[97]  I. Tomlinson,et al.  The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase , 2003, Annals of medicine.

[98]  L. Ellis,et al.  Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells* , 2002, The Journal of Biological Chemistry.

[99]  G. Semenza.  Signal transduction to hypoxia-inducible factor 1. , 2002, Biochemical pharmacology.

[100]  A. Harris,et al.  Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. , 2002, International journal of radiation oncology, biology, physics.

[101]  D. Kenan,et al.  Direct interactions between corepressors and coactivators permit the integration of nuclear receptor-mediated repression and activation. , 2002, Molecular endocrinology.

[102]  Michael C. Montalto,et al.  Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. , 2002, Cancer research.

[103]  C. Eng.  Role of PTEN, a Lipid Phosphatase Upstream Effector of Protein Kinase B, in Epithelial Thyroid Carcinogenesis , 2002, Annals of the New York Academy of Sciences.

[104]  G. Semenza,et al.  HIF-1 and tumor progression: pathophysiology and therapeutics. , 2002, Trends in molecular medicine.

[105]  R. Knuechel,et al.  Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[106]  G. Semenza,et al.  Rac1 Activity Is Required for the Activation of Hypoxia-inducible Factor 1* , 2001, The Journal of Biological Chemistry.

[107]  M. Schindl,et al.  Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[108]  G. Semenza,et al.  HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression , 2001, Molecular and Cellular Biology.

[109]  R. Tuttle,et al.  Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. , 2001, Surgery.

[110]  P. Ratcliffe,et al.  Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. , 2001, Human molecular genetics.

[111]  P Vaupel,et al.  Biological consequences of tumor hypoxia. , 2001, Seminars in oncology.

[112]  A. Gingras,et al.  Regulation of translation initiation by FRAP/mTOR. , 2001, Genes & development.

[113]  G. Semenza,et al.  Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. , 2001, Cancer research.

[114]  P. Vaupel,et al.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.

[115]  D. Roymans,et al.  Phosphatidylinositol 3-kinases in tumor progression. , 2001, European journal of biochemistry.

[116]  J. Pouysségur,et al.  Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. , 2000, Biochemical pharmacology.

[117]  G. Semenza,et al.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. , 2000, Cancer research.

[118]  P. Allavena,et al.  Hepatocyte Growth Factor (HGF) Stimulates Tumor Cells to Release Chemokines Active in Recruiting Dendritic Cells , 2000 .

[119]  A. Koong,et al.  Loss of PTEN facilitates HIF-1-mediated gene expression. , 2000, Genes & development.

[120]  K. Ang,et al.  In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[121]  G. Semenza,et al.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.

[122]  L. Mariani,et al.  Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. , 1999, The American journal of pathology.

[123]  J. Pouysségur,et al.  p42/p44 Mitogen-activated Protein Kinases Phosphorylate Hypoxia-inducible Factor 1α (HIF-1α) and Enhance the Transcriptional Activity of HIF-1* , 1999, The Journal of Biological Chemistry.

[124]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[125]  S. Schreiber,et al.  Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[126]  G. Semenza,et al.  Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. , 1998, American journal of physiology. Lung cellular and molecular physiology.

[127]  J M Ward,et al.  Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[128]  W. McGuire,et al.  Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. , 1993, Journal of the National Cancer Institute.

[129]  R K Jain,et al.  Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. , 1990, Cancer research.

[130]  A. Sharma.  Molecular Cellular Biology , 2011 .

[131]  A. C. Williams,et al.  Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. , 2007, Nature cell biology.

[132]  Rosa Bernardi,et al.  PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. , 2006, Nature.

[133]  Eyal Gottlieb,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[134]  David G. Watson,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[135]  V. Erdmann,et al.  Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[136]  Brian Keith,et al.  Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. , 2003, Molecular and cellular biology.

[137]  Hao Zheng,et al.  Novartis Foundation Symposium , 2003 .

[138]  R. Gillies,et al.  pH and chemotherapy. , 2001, Novartis Foundation symposium.

[139]  Randall,et al.  Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12–rapamycin-associated protein , 1999 .